Cargando…

Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups

Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial hypertension (PAH), chronic thromboembolic PH (g...

Descripción completa

Detalles Bibliográficos
Autores principales: Chebib, Nader, Mornex, Jean-François, Traclet, Julie, Philit, François, Khouatra, Chahera, Zeghmar, Sabrina, Turquier, Ségolène, Cottin, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012471/
https://www.ncbi.nlm.nih.gov/pubmed/29671674
http://dx.doi.org/10.1177/2045894018775056
_version_ 1783333933638746112
author Chebib, Nader
Mornex, Jean-François
Traclet, Julie
Philit, François
Khouatra, Chahera
Zeghmar, Sabrina
Turquier, Ségolène
Cottin, Vincent
author_facet Chebib, Nader
Mornex, Jean-François
Traclet, Julie
Philit, François
Khouatra, Chahera
Zeghmar, Sabrina
Turquier, Ségolène
Cottin, Vincent
author_sort Chebib, Nader
collection PubMed
description Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial hypertension (PAH), chronic thromboembolic PH (group 4), and group 5 PH. We retrospectively analyzed consecutive incident PH patients in a single center between January 2006 and November 2014. Data were acquired from a prospective database. Clinical, functional, and hemodynamic characteristics, as well as survival, were compared between the four groups of precapillary PH. A total of 363 patients were analyzed; 164 patients (45.2%) belonged to group 1 PAH, 109 (30%) to group 3 PH, 65 (17.9%) to group 4 PH, and 25 (6.9%) to group 5 PH. Group 3 patients were predominantly male and were more frequently in New York Heart Association (NYHA) class III/IV. Patients with group 3 and 4 PH were older, had significantly lower 6-min walking distance (6MWD), higher mean pulmonary arterial pressure, higher pulmonary vascular resistance (PVR), and lower cardiac index (CI) than PAH patients. Group 3 and 5 patients had significantly lower total lung capacity (TLC), forced vital capacity (FVC), and FEV1; group 3 patients had the lowest carbon monoxide transfer coefficient values. PH therapy was used in 90.9% of group 3 patients. Univariate analysis of prognostic factors in the overall population showed that age, male gender, NYHA class, groups 3 and 4 PH (vs. PAH), 6MWD, FVC, TLC, carbon monoxide transfer coefficient (KCO), PVR, CI, and venous oxygen saturation were significantly associated with greater mortality. Multivariate analysis showed that age, PH group 4, 6MWD, and KCO but no longer PH group 3 were significantly associated with mortality. Patients with group 3 PH are older, have more severe baseline presentation and lower survival rates than PAH patients in univariate analysis, that seemed to be related to older age.
format Online
Article
Text
id pubmed-6012471
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-60124712018-07-05 Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups Chebib, Nader Mornex, Jean-François Traclet, Julie Philit, François Khouatra, Chahera Zeghmar, Sabrina Turquier, Ségolène Cottin, Vincent Pulm Circ Research Article Group 3 pulmonary hypertension (PH) is a common complication of advanced chronic lung disease. Our hypothesis was that group 3 PH is associated with a more severe baseline presentation and a more severe prognosis compared to group 1 pulmonary arterial hypertension (PAH), chronic thromboembolic PH (group 4), and group 5 PH. We retrospectively analyzed consecutive incident PH patients in a single center between January 2006 and November 2014. Data were acquired from a prospective database. Clinical, functional, and hemodynamic characteristics, as well as survival, were compared between the four groups of precapillary PH. A total of 363 patients were analyzed; 164 patients (45.2%) belonged to group 1 PAH, 109 (30%) to group 3 PH, 65 (17.9%) to group 4 PH, and 25 (6.9%) to group 5 PH. Group 3 patients were predominantly male and were more frequently in New York Heart Association (NYHA) class III/IV. Patients with group 3 and 4 PH were older, had significantly lower 6-min walking distance (6MWD), higher mean pulmonary arterial pressure, higher pulmonary vascular resistance (PVR), and lower cardiac index (CI) than PAH patients. Group 3 and 5 patients had significantly lower total lung capacity (TLC), forced vital capacity (FVC), and FEV1; group 3 patients had the lowest carbon monoxide transfer coefficient values. PH therapy was used in 90.9% of group 3 patients. Univariate analysis of prognostic factors in the overall population showed that age, male gender, NYHA class, groups 3 and 4 PH (vs. PAH), 6MWD, FVC, TLC, carbon monoxide transfer coefficient (KCO), PVR, CI, and venous oxygen saturation were significantly associated with greater mortality. Multivariate analysis showed that age, PH group 4, 6MWD, and KCO but no longer PH group 3 were significantly associated with mortality. Patients with group 3 PH are older, have more severe baseline presentation and lower survival rates than PAH patients in univariate analysis, that seemed to be related to older age. SAGE Publications 2018-04-05 /pmc/articles/PMC6012471/ /pubmed/29671674 http://dx.doi.org/10.1177/2045894018775056 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Article
Chebib, Nader
Mornex, Jean-François
Traclet, Julie
Philit, François
Khouatra, Chahera
Zeghmar, Sabrina
Turquier, Ségolène
Cottin, Vincent
Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
title Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
title_full Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
title_fullStr Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
title_full_unstemmed Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
title_short Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
title_sort pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6012471/
https://www.ncbi.nlm.nih.gov/pubmed/29671674
http://dx.doi.org/10.1177/2045894018775056
work_keys_str_mv AT chebibnader pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups
AT mornexjeanfrancois pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups
AT tracletjulie pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups
AT philitfrancois pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups
AT khouatrachahera pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups
AT zeghmarsabrina pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups
AT turquiersegolene pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups
AT cottinvincent pulmonaryhypertensioninchroniclungdiseasescomparisontootherpulmonaryhypertensiongroups